Benralizumab

• A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases (CLIPS) Pending
  2023-508533-14-00 Phase III 3 countries AstraZeneca AB
• BIOlogical treatment GRAdual Interval Longing in severe Asthma (BIO-GRAIL) Pending
  2025-524741-28-00 Phase IV 1 country Amsterdam UMC Stichting
• A trial to learn how well benralizumab works and how safe it is when given in addition to standard asthma treatments in people with eosinoph… Ended
  2024-515162-13-00 Phase III 7 countries AstraZeneca AB
• A study to assess efficacy and safety of benralizumab in paediatric patients with severe eosinophilic asthma (severe asthma marked by high… Ended
  2022-501344-14-00 Phase III 5 countries Astrazeneca AB
• Predictive Signature of Benralizumab Response. BENRAPRED Study. Ended
  2024-514843-27-00 Phase IV 1 country Centre Hospitalier Universitaire De Nantes
• A study to evaluate if benralizumab may be beneficial in the treatment of Hypereosinophilic Syndrome (HES). Ended
  2023-510455-28-00 Phase III 9 countries AstraZeneca AB
• Efficacy and Safety of Benralizumab in EGPA compared to mepolizumab. Ended
  2023-510248-19-00 Phase III 4 countries AstraZeneca AB
• The Effect of Benralizumab on Structural and Lung Function Changes in Patients with Severe Asthma Ended
  2023-506614-40-00 Phase IV 2 countries Astrazeneca AB
• A study to evaluate the efficacy and safety of repeating dose of benralizumab administered SC versus placebo in patients with Eosinophilic C… Ended
  2023-507987-38-00 Phase III 5 countries AstraZeneca AB
• Non-inferiority study of GSK3511294 (depemokimab) compared with mepolizumab or benralizumab in participants with severe asthma with an eosin… Ended
  2023-510230-84-00 Phase III 12 countries Glaxosmithkline Research & Development Limited
• Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent Exace… Ended
  2022-503050-39-00 Phase III 13 countries AstraZeneca AB

Showing 1–11 of 11 trials